[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648796":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":61,"collaborators":20,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":20,"enrollmentInfo":73,"targetDuration":20,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":87,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Illinois at Chicago","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who will receive haloperidol","EXPERIMENTAL","Patients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis",[13],"Drug: Haloperidol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Haloperidol","This intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Wesley Eilbert, MD","University of Illinois Health","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Mason A Bartman, MD","CONTACT","8178972205","mbartman@uic.edu",{"name":23,"role":29,"phone":33,"phoneExt":20,"email":34},"6302944225","weilbert@uic.edu",[36],{"facility":37,"status":20,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of Illinois Hospital","Chicago","Illinois","60612","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-87.65005,41.85003,{"lat":47,"lon":46},[50,51,52,53,54,57,59],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":23,"role":29,"phone":33,"phoneExt":20,"email":34},{"name":28,"role":25,"phone":20,"phoneExt":20,"email":20},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"name":55,"role":56,"phone":20,"phoneExt":20,"email":20},"Shaveta Khosla, Khosla","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":20,"phoneExt":20,"email":20},"Drew Posen, PharmD",{"name":60,"role":56,"phone":20,"phoneExt":20,"email":20},"Urvi Dubey, BS",{"type":25,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Mason Bartman","MD","100648796","early-phase-1-haloperidol-for-outpatient-symptom-management-in-patients-diagnosed-with-cannabinoid-hyperemesis-syndrome-in-the-emergrency-department-100648796",false,"NCT07726069","Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department","Inclusion Criteria:\n\n\\- Patients who meet ROME-4 diagnostic criteria for cannabinoid hyperemesis syndrome\n\nExclusion Criteria:\n\n* Already on dopamine agonist\u002Fantagonist therapy for another condition\n* Parkinson's disease\n* Lewy body dementia\n* Men with QTc \\> 450\n* Women with QTc \\> 460\n* Patients with documented allergy to haloperidol\n* Patients with known functional prolactinomas\n* Patients who are breastfeeding\n* Patients under the age of 18\n* Patients who are pregnant\n* Patients who are in the prison system\n* Patients who are unable to consent",true,"ALL","18 Years",{"count":74,"type":75},100,"ESTIMATED","INTERVENTIONAL",[78],"EARLY_PHASE1","Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.",[81],"Cannabinoid Hyperemesis Syndrome",[83,84,85,86],"chs","cannabinoid hyperemesis syndrome","haldol","haloperidol","NOT_YET_RECRUITING","2026-08-13",{"date":90,"type":91},"2026-08-17","ACTUAL",{"date":93,"type":75},"2026-11",{"date":95,"type":75},"2028-01",{"name":5,"class":6},1]